These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35861550)

  • 81. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
    Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
    PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.
    Sevenich M; van den Heuvel J; Gering I; Mohrlüder J; Willbold D
    J Virol; 2022 Jul; 96(13):e0068522. PubMed ID: 35674432
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Computational exploration of natural peptides targeting ACE2.
    He M; Wang Y; Huang S; Zhao N; Cheng M; Zhang X
    J Biomol Struct Dyn; 2022 Oct; 40(17):8018-8029. PubMed ID: 33826484
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
    Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
    Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.
    Jaiswal G; Yaduvanshi S; Kumar V
    J Biomol Struct Dyn; 2022 Sep; 40(14):6671-6681. PubMed ID: 33645443
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.
    Vanslambrouck JM; Neil JA; Rudraraju R; Mah S; Tan KS; Groenewegen E; Forbes TA; Karavendzas K; Elliott DA; Porrello ER; Subbarao K; Little MH
    J Virol; 2024 Mar; 98(3):e0180223. PubMed ID: 38334329
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution.
    Erausquin E; Glaser F; Fernández-Recio J; López-Sagaseta J
    Acta Crystallogr D Struct Biol; 2022 Sep; 78(Pt 9):1156-1170. PubMed ID: 36048155
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry.
    Haga S; Yamamoto N; Nakai-Murakami C; Osawa Y; Tokunaga K; Sata T; Yamamoto N; Sasazuki T; Ishizaka Y
    Proc Natl Acad Sci U S A; 2008 Jun; 105(22):7809-14. PubMed ID: 18490652
    [TBL] [Abstract][Full Text] [Related]  

  • 93. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
    Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach.
    Aljindan RY; Al-Subaie AM; Al-Ohali AI; Kumar D T; Doss C GP; Kamaraj B
    Comput Biol Med; 2021 Aug; 135():104654. PubMed ID: 34346317
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adaptation of SARS-CoV-2 to ACE2
    Li K; Verma A; Li P; Ortiz ME; Hawkins GM; Schnicker NJ; Szachowicz PJ; Pezzulo AA; Wohlford-Lenane CL; Kicmal T; Meyerholz DK; Gallagher T; Perlman S; McCray PB
    J Virol; 2024 Jan; 98(1):e0151023. PubMed ID: 38168680
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells.
    Yang H; Yuan H; Zhao X; Xun M; Guo S; Wang N; Liu B; Wang H
    Virol Sin; 2022 Jun; 37(3):380-389. PubMed ID: 35272059
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.
    Zhang Y; Hu S; Wang J; Xue Z; Wang C; Wang N
    Virology; 2021 Feb; 554():83-88. PubMed ID: 33387788
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction.
    Singh R; Kumar A; Rane JS; Khan R; Tripathi G; Ajay AK; Prakash A; Ray S
    Sci Rep; 2022 Oct; 12(1):17038. PubMed ID: 36220880
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Virtual and biochemical screening to identify the inhibitors of binding between SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2.
    Park C; Eun C
    J Mol Graph Model; 2022 Jul; 114():108206. PubMed ID: 35504156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.